Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IM-A5N1
- Development stage
- Preclinical
- Lead developer
- ITabMed
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IM-A5N1 is an investigational bispecific monoclonal antibody developed by ITabMed for the treatment of Non-Hodgkin lymphoma (NHL). Utilizing the company's proprietary iTAb™ (Immune-Targeting Antibody) platform, IM-A5N1 is designed as a T-cell engager that simultaneously targets the CD20 antigen on malignant B-cells and the CD3 receptor on T-cells. By bridging these two cell types, the drug facilitates the formation of an immunological synapse, leading to the localized activation of T-cells and the subsequent redirected lysis of CD20-positive lymphoma cells. It is currently in early-stage development as part of ITabMed's pipeline of immune-targeted therapies.
02
Targets
CD3E (T-cell surface glycoprotein CD3 epsilon chain receptor)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on IM-A5N1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM-A5N1.